Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med [Internet]. 2017 [cited 2021 Jun 28];376:125–35. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1607427

Singh S, Halperin DM, Myrehaug S, Herrmann K, Pavel M, Kunz PL, et al. [ 177 Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study. JCO [Internet]. 2024 [cited 2024 Apr 24];42:LBA588–LBA588. Available from: https://ascopubs.org/doi/10.1200/JCO.2024.42.3_suppl.LBA588

Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med [Internet]. 2021 [cited 2021 Jun 28];NEJMoa2107322. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2107322

Pomykala KL, Hadaschik BA, Sartor O, Gillessen S, Sweeney CJ, Maughan T, et al. Next generation radiotheranostics promoting precision medicine. Annals of Oncology [Internet]. 2023 [cited 2023 Sep 24];34:507–19. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0923753423001138

Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, et al. 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. The Lancet Oncology [Internet]. 2021 [cited 2023 Jun 10];22:1752–63. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1470204521005726

Aerts A, Eberlein U, Holm S, Hustinx R, Konijnenberg M, Strigari L, et al. EANM position paper on the role of radiobiology in nuclear medicine. Eur J Nucl Med Mol Imaging [Internet]. 2021 [cited 2022 Apr 6];48:3365–77. Available from: https://link.springer.com/10.1007/s00259-021-05345-9

EANM Radiobiology Working Group:, Pouget J-P, Konijnenberg M, Eberlein U, Glatting G, Gabina PM, et al. An EANM position paper on advancing radiobiology for shaping the future of nuclear medicine. Eur J Nucl Med Mol Imaging [Internet]. 2023 [cited 2023 Jan 19];50:242–6. Available from: https://link.springer.com/10.1007/s00259-022-05934-2

Rodney Withers H, Taylor JMG, Maciejewski B. Treatment volume and tissue tolerance. International Journal of Radiation Oncology*Biology*Physics [Internet]. 1988 [cited 2024 Feb 21];14:751–9. Available from: https://linkinghub.elsevier.com/retrieve/pii/0360301688900983

Begg AC, Terry NHA. The sensitivity of normal stroma to fractionated radiotherapymeasured by a tumour growth rate assay. Radiotherapy and Oncology [Internet]. 1984 [cited 2024 Feb 3];2:333–41. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0167814084800766

Williams MV, Denekamp J, Fowler JF. A review of ratios for experimental tumors: Implications for clinical studies of altered fractionation. International Journal of Radiation Oncology*Biology*Physics [Internet]. 1985 [cited 2024 Feb 3];11:87–96. Available from: https://linkinghub.elsevier.com/retrieve/pii/0360301685903669

Bentzen SM, Ritter MA. The α/β ratio for prostate cancer: What is it, really? Radiotherapy and Oncology [Internet]. 2005 [cited 2024 Feb 3];76:1–3. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0167814005002227

Baumann M, Dubois W, Suit HD. Response of human squamous cell carcinoma xenografts of different sizes to irradiation: relationship of clonogenic cells, cellular radiation sensitivity in vivo, and tumor rescuing units. Radiat Res. 1990;123:325–30.

Article  PubMed  CAS  Google Scholar 

Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. BJR [Internet]. 1989 [cited 2021 Jul 6];62:679–94. Available from: http://www.birpublications.org/doi/10.1259/0007-1285-62-740-679

Bentzen SørM. Quantitative Clinical Radiobiology. Acta Oncologica [Internet]. 1993 [cited 2021 Feb 5];32:259–75. Available from: http://www.tandfonline.com/doi/full/10.3109/02841869309093594

Dörr W. Radiation effect in normal tissue - principles of damage and protection. Nuklearmedizin. 2010;49(Suppl 1):S53-58.

PubMed  Google Scholar 

Thames HD, Rodney Withers H, Peters LJ, Fletcher GH. Changes in early and late radiation responses with altered dose fractionation: Implications for dose-survival relationships. International Journal of Radiation Oncology*Biology*Physics [Internet]. 1982 [cited 2023 May 27];8:219–26. Available from: https://linkinghub.elsevier.com/retrieve/pii/036030168290517X

Pouget J-P, Chan TA, Galluzzi L, Constanzo J. Radiopharmaceuticals as combinatorial partners for immune checkpoint inhibitors. Trends in Cancer [Internet]. 2023 [cited 2023 Sep 2];S2405803323001413. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2405803323001413

Fowler JF. Radiobiological aspects of low dose rates in radioimmunotherapy. International Journal of Radiation Oncology*Biology*Physics [Internet]. 1990 [cited 2021 Feb 16];18:1261–9. Available from: https://linkinghub.elsevier.com/retrieve/pii/036030169090467X

Bentzen SM, Thames HD. Tumor volume and local control probability: Clinical data and radiobiological interpretations. International Journal of Radiation Oncology*Biology*Physics [Internet]. 1996 [cited 2021 Jul 6];36:247–51. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0360301696002428

Pouget J-P, Lozza C, Deshayes E, Boudousq V, Navarro-Teulon I. Introduction to Radiobiology of Targeted Radionuclide Therapy. Front Med [Internet]. 2015 [cited 2021 Mar 31];2. Available from: http://www.frontiersin.org/Nuclear_Medicine/10.3389/fmed.2015.00012/abstract

Thames HD. On the origin of dose fractionation regimens in radiotherapy. Seminars in Radiation Oncology [Internet]. 1992 [cited 2021 Feb 9];2:3–9. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1053429605800438

Ruigrok EAM, Tamborino G, de Blois E, Roobol SJ, Verkaik N, De Saint-Hubert M, et al. In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T. Eur J Nucl Med Mol Imaging [Internet]. 2022 [cited 2022 Aug 31];49:3627–38. Available from: https://link.springer.com/10.1007/s00259-022-05821-w

Pouget J-P, Santoro L, Raymond L, Chouin N, Bardiès M, Bascoul-Mollevi C, et al. Cell Membrane is a More Sensitive Target than Cytoplasm to Dense Ionization Produced by Auger Electrons. Radiation Research [Internet]. 2008 [cited 2021 Feb 9];170:192–200. Available from: http://www.bioone.org/doi/10.1667/RR1359.1

Marcatili S, Pichard A, Courteau A, Ladjohounlou R, Navarro-Teulon I, Repetto-Llamazares A, et al. Realistic multi-cellular dosimetry for 177 Lu-labelled antibodies: model and application. Phys Med Biol [Internet]. 2016 [cited 2021 Jun 2];61:6935–52. Available from: https://iopscience.iop.org/article/10.1088/0031-9155/61/19/6935

Stokke C, Gnesin S, Tran-Gia J, Cicone F, Holm S, Cremonesi M, et al. EANM guidance document: dosimetry for first-in-human studies and early phase clinical trials. Eur J Nucl Med Mol Imaging [Internet]. 2024 [cited 2024 Feb 28]; Available from: https://link.springer.com/10.1007/s00259-024-06640-x

Gear J, Stokke C, Terwinghe C, Gnesin S, Sandström M, Tran-Gia J, et al. EANM enabling guide: how to improve the accessibility of clinical dosimetry. Eur J Nucl Med Mol Imaging [Internet]. 2023 [cited 2024 Feb 28];50:1861–8. Available from: https://link.springer.com/10.1007/s00259-023-06226-z

Roth D, Gustafsson J, Warfvinge CF, Sundlöv A, Åkesson A, Tennvall J, et al. Dosimetric Quantities in Neuroendocrine Tumors over Treatment Cycles with 177 Lu-DOTATATE. J Nucl Med [Internet]. 2022 [cited 2023 May 20];63:399–405. Available from: http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.121.262069

Mileva M, Marin G, Levillain H, Artigas C, Van Bogaert C, Marin C, et al. Prediction of 177 Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study. J Nucl Med [Internet]. 2023 [cited 2024 Jan 31];jnumed.123.265987. Available from: http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.123.265987

Hebert K, Santoro L, Monnier M, Castan F, Berkane I, Assénat E, et al. Absorbed Dose–Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine. Journal of Nuclear Medicine [Internet]. 2024;65:923–30. Available from: https://doi.org/10.2967/jnumed.123.267023

Alipour R, Jackson P, Bressel M, Hogg A, Callahan J, Hicks RJ, et al. The relationship between tumour dosimetry, response, and overall survival in patients with unresectable Neuroendocrine Neoplasms (NEN) treated with 177Lu DOTATATE (LuTate). Eur J Nucl Med Mol Imaging [Internet]. 2023 [cited 2024 Feb 6];50:2997–3010. Available from: https://link.springer.com/10.1007/s00259-023-06257-6

Violet J, Sandhu S, Iravani A, Ferdinandus J, Thang S-P, Kong G, et al. Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177 Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer. J Nucl Med [Internet]. 2020 [cited 2023 Oct 15];61:857–65. Available from: http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.119.236414

Violet J, Jackson P, Ferdinandus J, Sandhu S, Akhurst T, Iravani A, et al. Dosimetry of 177 Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes. J Nucl Med [Internet]. 2019 [cited 2023 Nov 14];60:517–23. Available from: http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.118.219352

Murray I, Chittenden SJ, Denis-Bacelar AM, Hindorf C, Parker CC, Chua S, et al. The potential of 223Ra and 18F-fluoride imaging to predict bone lesion response to treatment with 223Ra-dichloride in castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging [Internet]. 2017 [cited 2023 Jul 10];44:1832–44. Available from: http://link.springer.com/10.1007/s00259-017-3744-y

Danieli R, Milano A, Gallo S, Veronese I, Lascialfari A, Indovina L, et al. Personalized Dosimetry in Targeted Radiation Therapy: A Look to Methods, Tools and Critical Aspects. JPM [Internet]. 2022 [cited 2023 May 19];12:205. Available from: https://www.mdpi.com/2075-4426/12/2/205

Bodei L, Kidd M, Paganelli G, Grana CM, Drozdov I, Cremonesi M, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging [Internet]. 2015 [cited 2019 Nov 2];42:5–19. Available from: http://link.springer.com/10.1007/s00259-014-2893-5

Dale RG. Dose-rate effects in targeted radiotherapy. Phys Med Biol [Internet]. 1996 [cited 2021 Feb 9];41:1871–84. Available from: https://iopscience.iop.org/article/10.1088/0031-9155/41/10/001

Down JD, Easton DF, Steel GG. Repair in the mouse lung during low dose-rate irradiation. Radiotherapy and Oncology [Internet]. 1986 [cited 2024 Jan 15];6:29–42. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0167814086801074

Dörr W, Schmidt M. Normal Tissue Radiobiology. Comprehensive Biomedical Physics [Internet]. Elsevier; 2014 [cited 2024 Feb 3]. p. 75–95. Available from: https://linkinghub.elsevier.com/retrieve/pii/B9780444536327008054

Kind F, Michalski K, Yousefzadeh-Nowshahr E, Meyer PT, Mix M, Ruf J. Bone marrow impairment during early [177Lu]PSMA-617 radioligand therapy: Haematotoxicity or tumour progression? EJNMMI Res [Internet]. 2022 [cited 2023 Oct 15];12:20. Available from: https://ejnmmires.springeropen.com/articles/10.1186/s13550-022-00891-1

Van Essen M, Krenning EP, Kam BLR, De Herder WW, Feelders RA, Kwekkeboom DJ. Salvage Therapy with 177 Lu-Octreotate in Patients with Bronchial and Gastroenteropancreatic Neuroendocrine Tumors. J Nucl Med [Internet]. 2010 [cited 2024 Feb 5];51:383–90. Available from: http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.109.068957

Chittenden SJ, Hindorf C, Parker CC, Lewington VJ, Pratt BE, Johnson B, et al. A Phase 1, Open-Label Study of the Biodistribution, Pharmacokinetics, and Dosimetry of 223 Ra-Dichloride in Patients with Hormone-Refractory Prostate Cancer and Skeletal Metastases. J Nucl Med [Internet]. 2015 [cited 2023 Nov 17];56:1304–9. Available from: http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.115.157123

Herrmann K, Rahbar K, Eiber M, Sparks R, Baca N, Krause BJ, et al. Renal and Multiorgan Safety of 177 Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy. J Nucl Med [Internet]. 2023 [cited 2024 Jan 15];jnumed.123.265448. Available from: http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.123.265448

Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med [Internet]. 2021 [cited 2021 Oct 27];385:1091–103. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2107322

Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. The Lancet [Internet]. 2021 [cited 2023 Oct 15];397:797–804. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673621002373

Bergsma H, Konijnenberg MW, Kam BLR, Teunissen JJM, Kooij PP, De Herder WW, et al. Subacute haematotoxicity after PRRT with 177Lu-DOTA-octreotate: prognostic factors, incidence and course. Eur J Nucl Med Mol Imaging [Internet]. 2016 [cited 2023 Oct 15];43:453–63. Available from: http://link.springer.com/10.1007/s00259-015-3193-4

Hagmarker L, Svensson J, Rydén T, Van Essen M, Sundlöv A, Gleisner KS, et al. Bone Marrow Absorbed Doses and Correlations with Hematologic Response During 177 Lu-DOTATATE Treatments Are Influenced by Image-Based Dosimetry Method and Presence of Skeletal Metastases. J Nucl Med [Internet]. 2019 [cited 2023 Oct 15];60:1406–13. Available from: http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.118.225235

Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, et al. [177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl Med [Internet]. 2001 [cited 2024 Feb 5];28:1319–25. Available from: http://link.springer.com/10.1007/s002590100574

Morgantetti G, Ng KL, Samaratunga H, Rhee H, Gobe GC, Wood ST. Prostate specific membrane antigen (PSMA) expression in vena cava tumour thrombi of clear cell renal cell carcinoma suggests a role for PSMA-driven tumour neoangiogenesis. Transl Androl Urol. 2019;8:S147–55. https://doi.org/10.21037/tau.2019.04.10.

Article  PubMed  PubMed Central  Google Scholar 

Köst S, Dörr W, Keinert K, Glaser F-H, Endert G, Herrmann T. Effect of dose and dose-distribution in damage to the kidney following abdominal radiotherapy. International Journal of Radiation Biology [Internet]. 2002 [cited 2024 Jan 14];78:695–702. Available from: http://www.tandfonline.com/doi/full/10.1080/09553000210134791

Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch A, et al. Use of Normal Tissue Complication Probability Models in the Clinic. International Journal of Radiation Oncology*Biology*Physics [Internet]. 2010 [cited 2024 Apr 12];76:S10–9. Available from: https://linkinghub.elsevier.com/retrieve/pii/S036030160903288X

Bergsma H, Konijnenberg MW, Van Der Zwan WA, Kam BLR, Teunissen JJM, Kooij PP, et al. Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate. Eur J Nucl Med Mol Imaging [Internet]. 2016 [cited 2024 Feb 3];43:1802–11. Available from: http://link.springer.com/10.1007/s00259-016-3382-9

Bernard BF, Krenning EP, Breeman WA, Rolleman EJ, Bakker WH, Visser TJ, et al. D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. J Nucl Med. 1997;38:1929–33.

PubMed  CAS  Google Scholar 

Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, et al. 177 Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy. J Nucl Med [Internet]. 2016 [cited 2023 May 20];57:1006–13. Available from: http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.115.168443

Deasy JO, Moiseenko V, Marks L, Chao KSC, Nam J, Eisbruch A. Radiotherapy Dose–Volume Effects on Salivary Gland Function. International Journal of Radiation Oncology*Biology*Physics [Internet]. 2010 [cited 2024 Sep 30];76:S58–63. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0360301609032891

Tönnesmann R, Meyer P, Eder M, Baranski A-C. [177Lu]Lu-PSMA-617 Salivary Gland Uptake Characterized by Quantitative In Vitro Autoradiography. Pharmaceuticals [Internet]. 2019 [cited 2023 Oct 15];12:18. Available from: http://www.mdpi.com/1424-8247/12/1/18

Feuerecker B, Tauber R, Knorr K, Heck M, Beheshti A, Seidl C, et al. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA. European Urology [Internet]. 2021 [cited 2023 Oct 15];79:343–50. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0302283820308770

Hohberg M, Eschner W, Schmidt M, Dietlein M, Kobe C, Fischer T, et al. Lacrimal Glands May Represent Organs at Risk for Radionuclide Therapy of Prostate Cancer with [177Lu]DKFZ-PSMA-617. Mol Imaging Biol [Internet]. 2016 [cited 2023 Oct 15];18:437–45. Available from: http://link.springer.com/10.1007/s11307-016-0942-0

Van Kalmthout L, Stam A, Gans R, Lam M. Visual deficit possibly caused by lutetium-177 PSMA treatment. BMJ Case Reports [Internet]. 2018 [cited 2023 Oct 15];bcr-2018–225508. Available from: https://casereports.bmj.com/lookup/doi/10.1136/bcr-2018-225508